{'fraction_non_alphanumeric': 0.016333938294010888, 'fraction_numerical': 0.0, 'mean_word_length': 6.885714285714286, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Methylnaltrexone for Opioid‐Induced Constipation in Pediatric Oncology Patients

Pediatric oncology patients can experience opioid‐induced constipation, which may not respond to laxative treatment. Methylnaltrexone is an opioid receptor antagonist that can reverse opioid‐induced constipation without affecting analgesia. Published literature on the use of methylnaltrexone in children is very limited. This retrospective review describes the effectiveness and safety of methylnaltrexone for opioid‐induced constipation in pediatric oncology patients.